- Home
- CTNT vs MBRX Comparison
CTNT vs MBRX Comparison
Compare CTNT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CTNT | MBRX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 6.1M |
| IPO Year | 2023 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CTNT | MBRX |
|---|---|---|
| Price | $1.48 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | 40.4K | ★ 249.0K |
| Earning Date | 05-04-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $455,805.00 | N/A |
| Revenue This Year | $235.67 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.03 | $0.25 |
| 52 Week High | $2.12 | $7.98 |
Technical Indicators
Market Signals| Indicator | CTNT | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 33.12 |
| Support Level | $1.36 | $0.37 |
| Resistance Level | $1.50 | $5.22 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 12.33 | 40.62 |
Price Performance
Historical ComparisonAbout CTNT Cheetah Net Supply Chain Service Inc.
Cheetah Net Supply Chain Service Inc is a one-stop services including Warehousing, Logistics, International trading & Supply Chain Finance, Etc. It operate in single segment Logistics and warehousing services which focuses on providing freight forwarding services for clients shipping goods from the U.S. to mainland China or Hong Kong. Its services include: cargo storage, freight forwarding, U.S. customs clearance, and (iv) labor services and cargo loading and unloading.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.